SCHEMBL9930746

SCHEMBL9930746

O=C(O)c1csc2c(Nc3ccccc3)ncnc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 2/20 0.49
CSNK2A1 P68400 7/20 0.47
CSNK2A2 P19784 4/20 0.47
LMNA P02545 3/20 0.47
CSNK2B P67870 3/20 0.47
THRB P10828 1/20 0.47
PTPN5 P54829 1/20 0.47
CLK1 P49759 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
EGFR P00533 4/20 0.45
MAP4K4 O95819 2/20 0.45
PIM1 P11309 2/20 0.45
MAP4K2 Q12851 2/20 0.45
DYRK1A Q13627 2/20 0.45
PIM3 Q86V86 2/20 0.45
AURKB Q96GD4 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
DYRK3 O43781 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9930406 0.84 MEN1 (0.44) DHODHCLK1MEN1KMT2APIM1
SCHEMBL29116330 0.81 MAPT (0.51) CSNK2A1LMNACLK1ALDH1A1KMT2A
SCHEMBL9930841 0.80 YTHDC1 (0.35) CSNK2A1CSNK2A2LMNACSNK2BTHRB
SCHEMBL20200108 0.80 KDM4E (0.50) ALDH1A1MEN1KMT2AEGFRABCG2
SCHEMBL9930279 0.79 SYK (0.39) ALDH1A1MAP4K4PIM1MAP4K2DYRK1A
SCHEMBL2234715 0.76 BRAF (0.47) CSNK2A1ALDH1A1MEN1KMT2AEGFR
SCHEMBL9930023 0.76 RAF1 (0.34) CSNK2A1CSNK2A2CSNK2BALDH1A1MAPK1
SCHEMBL9930605 0.76 SIRT2 (0.45) ALDH1A1KDM4EAURKARPS6KB1
SCHEMBL2312296 0.75 MAPT (0.48) CSNK2A1AURKARPS6KB1
SCHEMBL9930617 0.75 CSNK2A1 (0.39) CSNK2A1CSNK2A2LMNACSNK2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF DHODH 1441/4885CSNK2A1 598/4885CSNK2A2 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.